Skip to content

Feasibility of Polychromatic Light Emitting Diode System to Reduce Pain

A Polychromatic Light Emitting Diode System to Deliver Low Dose Light Directly Into a Peripheral Intravascular Catheter: A Pain Reduction Study

Status
Suspended
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03246282
Enrollment
150
Registered
2017-08-11
Start date
2017-02-08
Completion date
2018-12-31
Last updated
2017-11-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain

Brief summary

This study uses a prospective non-randomized, non-controlled design. One Hundred Fifty (150) subjects presenting with pain will be enrolled into a single treatment group The purpose of the study is to evaluate the feasibility of PLEDS for PIV catheter light delivery for pain reduction, through change between baseline average pain and final average VAS score. The absence of a control group is based on the following reason: The purpose of this investigation is to further the understanding of the feasibility of PLEDS for PIV catheter light delivery for pain management. Further, the results of this investigation will be used (internally only) to determine if subject-perceived reductions in pain warrant proceeding with more controlled, targeted and possibly randomized studies.

Detailed description

This study uses a prospective non-randomized, non-controlled design. One Hundred Fifty (150) subjects presenting with pain will be enrolled into a single treatment group The purpose of the study is to evaluate the feasibility of Polychromatic Light Emitting Diode System (PLEDS) for Peripheral Intravenous (PIV) catheter light delivery for pain reduction, through change between baseline average pain and final average VAS score. The absence of a control group is based on the following reason: The purpose of this investigation is to further the understanding of the feasibility of PLEDS for PIV catheter light delivery for pain management. Further, the results of this investigation will be used (internally only) to determine if subject-perceived reductions in pain warrant proceeding with more controlled, targeted and possibly randomized studies. PIV therapy has been used for decades as an effective therapy to maintain proper hydration and electrolyte levels. Additionally, PIV therapy can be infused with various agents, including supplements and pharmacological agents. Low-energy light therapy has been established as an alternative treatment for a myriad of medical conditions including reduction of pain. The concurrent administration of low-light therapy and PIV therapy may serve as a viable therapy for the treatment of pain associated with various medical conditions. Accordingly, this study is designed to assess the feasibility of low light therapy via PLEDS integrated into a standard PIV catheter for the purposes of reduction of pain.

Interventions

Non-coherent light source administered 365 nm, 630 nm, and 530 nm at an output intensity of 0.1 mW directly into an existing intravascular 20 gauge 1.0 catheter

250 ml of 0.9% Sodium Chloride Solution

20-gauge 1.0 catheter

Sponsors

White Clover Research Foundation
CollaboratorOTHER
White Clover Wellness and Research Center
CollaboratorUNKNOWN
John W. Reeves, MD
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* Voluntarily signed informed consent form (see Informed Consent Forms) * Ages 18-70 * Non-Pregnant Female Participants * Self-reported perceived pain score via Brief Pain Inventory - Short Form score of 2 or more. * No breastfeeding for 1 week prior to enrollment * Birth control measures to be used throughout the duration of the study for women of child bearing potential * Powerful antioxidants (e.g. oral antioxidants, Vitamin C and E, glutathione or Myer's cocktail IV infusion therapy) will not be used on treatment days

Exclusion criteria

* Active infection along potential intravenous catheter sites * Use of anti-inflammatory medications on day of treatment and no more than 400mg per day for over 30 days * Suffering from blood clotting disorders (hypercoagulable condition, thrombocytosis, etc.) * Participated in a clinical study in the last 14 days * Breastfeeding * Currently taking photosensitizing agents

Design outcomes

Primary

MeasureTime frameDescription
The use of polychromatic light therapy delivered through an intravascular catheter to assess the change in self-reported VAS pain score.2 weeksTo evaluate the feasibility of PLEDS for PIV catheter light delivery for the purposes of pain reduction, through assessing the change between baseline average pain (via Brief Pain Inventory - Short Form) and final average VAS score (via the Per Treatment VAS Score Form) following treatment administration.

Other

MeasureTime frameDescription
Subject Satisfaction2 weeksSelf-reported overall treatment satisfaction based on perceived response from treatment

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026